[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 24 of about 24
1. Ferrandina G, Salutari V, Testa A, Zannoni GF, Petrillo M, Scambia G: Recurrence in skeletal muscle from squamous cell carcinoma of the uterine cervix: a case report and review of the literature. BMC Cancer; 2006;6:169
MedlinePlus Health Information. consumer health - Cervical Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrence in skeletal muscle from squamous cell carcinoma of the uterine cervix: a case report and review of the literature.
  • Only two cases of late skeletal muscle recurrence from cervical cancer have been documented until now.
  • CASE PRESENTATION: A 38-year old patient, submitted to radical hysterectomy and pelvic lymphadenectomy for a squamous FIGO stage IB1 cervical carcinoma, presented after 76 months with a palpable, and painless swelling on the left hemithorax.
  • Pathology revealed the presence of metastasis of squamous cell carcinoma of similar morphology as the primary.
  • The patient was triaged to chemotherapy plus external radiotherapy.
  • CONCLUSION: A case of skeletal muscle recurrence from cervical cancer after a very long interval from primary diagnosis is reported.
  • Muscular pain or weakness, or just a palpable mass in a patient with a history of cancer has always to raise the suspicion of muscle metastasis.
  • [MeSH-major] Carcinoma, Squamous Cell / secondary. Muscle Neoplasms / secondary. Muscle, Skeletal. Thoracic Wall. Uterine Cervical Neoplasms

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg Oncol. 2000 Aug;7(7):526-34 [10947022.001]
  • [Cites] Obstet Gynecol. 2001 Oct;98(4):680-4 [11576588.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2002 Dec;14(6):447-8 [12512964.001]
  • [Cites] Cancer Radiother. 2003 Jun;7(3):187-9 [12834775.001]
  • [Cites] J Clin Oncol. 2004 Aug 1;22(15):3113-9 [15284262.001]
  • [Cites] Rinsho Hoshasen. 1990 Oct;35(11):1447-50 [2277431.001]
  • [Cites] Singapore Med J. 2003 Jun;44(6):302-3 [14560863.001]
  • [Cites] Clin Orthop Relat Res. 1993 Nov;(296):213-7 [8222429.001]
  • [Cites] Gynecol Oncol. 1994 Sep;54(3):372-6 [8088616.001]
  • [Cites] Ear Nose Throat J. 1995 Feb;74(2):118-21 [7705230.001]
  • [Cites] Isr J Med Sci. 1997 Oct;33(10):674-6 [9397142.001]
  • [Cites] Gynecol Oncol. 2005 Jul;98(1):54-8 [15904950.001]
  • [Cites] Gynecol Oncol. 1991 Jun;41(3):255-8 [1869105.001]
  • (PMID = 16800899.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Number-of-references] 14
  • [Other-IDs] NLM/ PMC1523362
  •  go-up   go-down


2. Cheng X, Cai S, Li Z, Tang M, Xue M, Zang R: The prognosis of women with stage IB1-IIB node-positive cervical carcinoma after radical surgery. World J Surg Oncol; 2004;2:47
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The prognosis of women with stage IB1-IIB node-positive cervical carcinoma after radical surgery.
  • BACKGROUND: Pelvic lymph nodes metastasis is an important prognostic factor for patients with cervical carcinoma.
  • However, the relationships between the number of positive nodes, site of metastases nodes, adjuvant therapy and the prognosis is controversial.
  • The purpose of this study was to investigate the influence of positive lymph nodes on the prognosis of Chinese women with stage IB1-IIB cervical carcinoma.
  • PATIENTS AND METHODS: Between January 1992 and December 1997, 398 women with International Federation of Gynecology and Obstetrics (FIGO) stage IB1-IIB cervical carcinoma underwent radical surgery in Cancer Hospital, Fudan University.
  • Cox proportional hazard model analysis showed that cellular differentiation, the number of positive nodes and adjuvant therapy to be the independent prognostic factors (P < 0.05).
  • The 5-year survival of the patients who had no adjuvant therapy (12.6%) was much lower than that (53.7%) of those with adjuvant therapy (P < 0.05).
  • However, there was no obvious difference between adjuvant radiotherapy, chemotherapy and chemo-radiotherapy (P > 0.05).
  • CONCLUSIONS: The prognosis of patients with stage IB1-IIB node-positive cervical carcinoma who underwent radical surgery alone was very poor.
  • Adjuvant therapy increases the survival rate, decreases the pelvic recurrence and distant metastasis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 2000 May;77(2):305-9 [10785483.001]
  • [Cites] Am J Obstet Gynecol. 1974 Jun 15;119(4):458-62 [4842590.001]
  • [Cites] Eur J Cancer. 2002 Jan;38(2):270-8 [11803143.001]
  • [Cites] J Clin Oncol. 2002 Feb 15;20(4):966-72 [11844818.001]
  • [Cites] Int J Gynecol Cancer. 2003 Sep-Oct;13(5):580-6 [14675339.001]
  • [Cites] CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30 [15661684.001]
  • [Cites] Gynecol Oncol. 1992 Aug;46(2):176-81 [1500019.001]
  • [Cites] Cancer. 1992 Jan 1;69(1):181-6 [1727662.001]
  • [Cites] Am J Obstet Gynecol. 1991 Jun;164(6 Pt 1):1520-7; discussion 1527-9 [2048598.001]
  • [Cites] Am J Roentgenol Radium Ther Nucl Med. 1972 Jan;114(1):116-22 [5061869.001]
  • [Cites] J Obstet Gynaecol Br Commonw. 1971 May;78(5):385-405 [5558325.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Jan 1;31(1):31-6 [7995765.001]
  • [Cites] Gynecol Oncol. 1994 Jul;54(1):4-9 [8020837.001]
  • [Cites] Gynecol Oncol. 1996 Apr;61(1):3-10 [8626113.001]
  • [Cites] Obstet Gynecol. 1998 Jun;91(6):977-81 [9611008.001]
  • [Cites] Cancer. 1999 Apr 1;85(7):1537-46 [10193944.001]
  • [Cites] N Engl J Med. 1999 Apr 15;340(15):1137-43 [10202164.001]
  • [Cites] N Engl J Med. 1999 Apr 15;340(15):1144-53 [10202165.001]
  • [Cites] N Engl J Med. 1999 Apr 15;340(15):1154-61 [10202166.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1339-48 [10334517.001]
  • [Cites] Am J Obstet Gynecol. 1999 Sep;181(3):518-24 [10486457.001]
  • [Cites] Semin Surg Oncol. 1999 Oct-Nov;17(3):161-7 [10504663.001]
  • [Cites] Gynecol Oncol. 1999 Dec;75(3):328-33 [10600284.001]
  • [Cites] J Clin Oncol. 2000 Apr;18(8):1606-13 [10764420.001]
  • [Cites] Gynecol Oncol. 1990 Jun;37(3):390-5 [2351324.001]
  • [Cites] Cancer. 1990 May 1;65(9):1923-7 [2372764.001]
  • [Cites] Eur J Gynaecol Oncol. 1989;10(5):326-36 [2806321.001]
  • [Cites] Am J Obstet Gynecol. 1972 Dec 1;114(7):954-62 [4645136.001]
  • [Cites] Lancet. 2001 Sep 8;358(9284):781-6 [11564482.001]
  • (PMID = 15606922.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC546224
  •  go-up   go-down


3. Kietpeerakool C, Lattiwongsakorn W, Srisomboon J: Incidence and predictors of febrile morbidity after radical hysterectomy and pelvic lymphadenectomy for early stage cervical cancer patients. Asian Pac J Cancer Prev; 2008 Apr-Jun;9(2):213-6
International Agency for Research on Cancer - Screening Group. diagnostics - Planning and Implementing Cervical Cancer Prevention and Control Programs: A Manual for Managers .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence and predictors of febrile morbidity after radical hysterectomy and pelvic lymphadenectomy for early stage cervical cancer patients.
  • Patients with FIGO stage IB-IIA cervical cancers who had undergone RHPL at Chiang Mai University Hospital between January 2003 and December 2005, were reviewed.
  • The clinical variables including the age at diagnosis, menopausal status, body mass index, previous cervical conization, tumor size, preoperative chemotherapy, preoperative anemia, operative time, and estimated blood loss were analyzed for prediction of postoperative febrile morbidity.
  • The majority of women (77.3%) were in FIGO stage IB1.
  • The most common histology was squamous cell carcinoma (69.2%).
  • [MeSH-major] Adenocarcinoma / surgery. Carcinoma, Squamous Cell / surgery. Fever / etiology. Hysterectomy / adverse effects. Lymph Node Excision / adverse effects. Postoperative Complications. Uterine Cervical Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Blood Loss, Surgical. Female. Humans. Incidence. Middle Aged. Risk Factors. Surgical Wound Infection / epidemiology. Surgical Wound Infection / etiology. Surgical Wound Infection / prevention & control. Treatment Outcome. Urinary Tract Infections / epidemiology. Urinary Tract Infections / etiology. Urinary Tract Infections / prevention & control


Advertisement
4. Mossa B, Mossa S, Marziani R: Adjuvant chemotherapy versus radiation therapy after radical surgery in high-risk positive node stage IB/IIA cervical cancer. Eur J Gynaecol Oncol; 2010;31(5):545-50
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant chemotherapy versus radiation therapy after radical surgery in high-risk positive node stage IB/IIA cervical cancer.
  • OBJECTIVE: The aim of this study was to evaluate whether the addition of adjuvant chemotherapy will improve the outcomes of high-risk patients with Stage IB, IIA squamous cervical carcinoma with positive pelvic and/or aortic nodes.
  • MATERIALS AND METHODS: 127 patients with Stage IB and IIA cervical carcinoma treated with radical hysterectomy and systematic pelvic/aortic lymphadenectomy (RS) and who had lymph node involvement, confirmed at the final histological examination were enrolled from January 1987 to December 2001.
  • All the patients received three cycles of adjuvant chemotherapy (AC) with cisplatin, bleomycin and vinblastine.
  • Seventy-seven patients had FIGO Stage IB1, 26 IB2 and 24 IIA.
  • The results were compared with those obtained from a group of 136 patients with comparable age, stage and lymph node involvement, on whom radical surgery, systematic pelvic/aortic lymphadenectomy (RS) and adjuvant radiotherapy (RT) was performed on period 1971-1984.
  • CONCLUSIONS: Adjuvant chemotherapy in high-risk patients for lymph node positivity did not produce statistically significant results in terms of overall and disease-free survival vs adjuvant radiotherapy; however, a group of these patients, approximately 10%, could receive benefit from the treatment.
  • [MeSH-major] Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / pathology. Sentinel Lymph Node Biopsy. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adult. Case-Control Studies. Chemotherapy, Adjuvant. Disease-Free Survival. Female. Follow-Up Studies. Humans. Hysterectomy. Middle Aged. Neoplasm Staging. Radiotherapy, Adjuvant


5. Kesic V: Management of cervical cancer. Eur J Surg Oncol; 2006 Oct;32(8):832-7
MedlinePlus Health Information. consumer health - Hysterectomy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of cervical cancer.
  • AIMS: The aim of the article was to review the current approach to management of cervical cancer.
  • METHODS: The relevant literature has served as a source for review of different options applied in the management of cervical cancer.
  • RESULTS: Treatment of invasive cervical cancer is affected by the stage of the disease, which is based on clinical evaluation.
  • Microinvasive carcinoma of the cervix has limited metastatic potential and therefore is most likely curable by non-radical treatment.
  • There is no standard management of stage Ib-IIa cervical carcinoma.
  • Most often, stage Ib1 cervical cancer is treated by radical hysterectomy with pelvic lymphadenectomy.
  • Radical vaginal trachelectomy with laparoscopic pelvic lymphadenectomy may be an option in small cervical cancer where preservation of fertility is desired.
  • There is lot of conflicting published work regarding the treatment of bulky stage Ib-IIa cervical cancer.
  • While some centers are performing primary surgery as for Ib1 disease followed by tailored postoperative radiation with or without chemotherapy, the others are in favor of primary chemo-radiation therapy.
  • Neoadjuvant chemotherapy followed by radical surgery has emerged as a possible alternative, which may improve a survival in patients with stage Ib2 disease.
  • Concomitant chemoradiation is becoming a new standard in treatment of advanced disease, because it has been clearly shown to improve disease-free, progression-free and overall survival.
  • Management of recurrent disease depends on previous treatment, site and extent of recurrence, disease-free interval and patient's performance status.
  • CONCLUSIONS: Treatment decisions should be individualized and based on multiple factors including the stage of the disease, age, medical condition of the patient, tumor-related factors and treatment preferences, to yield the best cure with minimum complications.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Hysterectomy / methods. Uterine Cervical Neoplasms / therapy
  • [MeSH-minor] Female. Humans. Lymph Node Excision. Radiotherapy, Adjuvant. Treatment Outcome

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16698223.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 42
  •  go-up   go-down


6. Plante M, Lau S, Brydon L, Swenerton K, LeBlanc R, Roy M: Neoadjuvant chemotherapy followed by vaginal radical trachelectomy in bulky stage IB1 cervical cancer: case report. Gynecol Oncol; 2006 May;101(2):367-70
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant chemotherapy followed by vaginal radical trachelectomy in bulky stage IB1 cervical cancer: case report.
  • BACKGROUND: We present 3 young women with bulky stage IB1 cervical cancer treated with neoadjuvant chemotherapy followed by laparoscopic pelvic node dissection and vaginal radical trachelectomy.
  • CASES: In the last year, we have treated 3 young women with large cervical lesions who wished to preserve fertility with induction chemotherapy followed by fertility-sparing surgery.
  • Three cycles of platinum-based combination chemotherapy were given and were well tolerated.
  • The 3 patients had a significant clinical response to chemotherapy.
  • A complete pathological response was confirmed by the absence of residual invasive cancer in the three trachelectomy specimens.
  • CONCLUSION: Neoadjuvant chemotherapy followed by a fertility-sparing surgery may become a valuable option for young women with bulky stage IB1 cervical cancer who wish to preserve their fertility potential.
  • [MeSH-major] Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / surgery
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant. Female. Gynecologic Surgical Procedures. Humans. Neoadjuvant Therapy. Neoplasm Staging

  • Genetic Alliance. consumer health - Vaginal cancer.
  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Gynecol Oncol. 2006 Oct;103(1):374; author reply 374-5 [16860854.001]
  • [CommentIn] Gynecol Oncol. 2006 Nov;103(2):763-4; author reply 764-5 [16952390.001]
  • (PMID = 16542714.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


7. Maneo A, Chiari S, Bonazzi C, Mangioni C: Neoadjuvant chemotherapy and conservative surgery for stage IB1 cervical cancer. Gynecol Oncol; 2008 Dec;111(3):438-43
Hazardous Substances Data Bank. EPIRUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant chemotherapy and conservative surgery for stage IB1 cervical cancer.
  • OBJECTIVES: To assess the effectiveness of chemo-surgical conservative therapy for stage IB1 cervical tumors in patients desiring to preserve fertility.
  • METHODS: From 1995 to April 2007 51 nulliparous patients with tumor <or=3 cm, aged <or=40 years with no uterine and lymphnode neoplastic involvement were evaluated.
  • When intraoperative frozen section revealed massive neoplastic cervical persistence a radical total hysterectomy was performed.
  • Following neoadjuvant treatment, pathological complete response was observed in 5 cases, in situ or microinvasive residue in 12 and stromal invasion >3 mm in 4.
  • Four women deemed ineligible for conservative surgery after chemotherapy and one refusing to preserve her genital apparatus underwent radical hysterectomy.
  • CONCLUSIONS: The high rate of pathological response confirms the effectiveness of the preoperative treatment for reducing the tumor volume allowing the removal only of a cervical cone instead of the entire cervix with cardinal ligaments as needed by radical trachelectomy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Adenocarcinoma / surgery. Adult. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / surgery. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Cisplatin / adverse effects. Conization. Epirubicin / administration & dosage. Epirubicin / adverse effects. Female. Humans. Hysterectomy. Ifosfamide / administration & dosage. Ifosfamide / adverse effects. Lymph Node Excision. Neoadjuvant Therapy. Neoplasm Staging. Paclitaxel / administration & dosage. Paclitaxel / adverse effects. Young Adult


8. Favero G, Lanowska M, Schneider A, Marnitz S, Köhler C: Laparoscopic pelvic lymphadenectomy in a patient with cervical cancer stage Ib1 complicated by a twin pregnancy. J Minim Invasive Gynecol; 2010 Jan-Feb;17(1):118-20
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic pelvic lymphadenectomy in a patient with cervical cancer stage Ib1 complicated by a twin pregnancy.
  • Cervical cancer is the most frequently observed malignancy during pregnancy.
  • To our knowledge, this is the first report of a twin pregnancy complicated by cancer of the uterine cervix that was successfully treated with laparoscopic pelvic lymphadenectomy and subsequently with neoadjuvant chemotherapy.
  • Cervical adenocarcinoma, grade 2, stage 1b1 with lymphovascular space invasion was diagnosed.
  • On the basis of tumor size and detection of lymphovascular space invasion, cisplatin as neoadjuvant chemotherapy was administered until week 32 of gestation, when a cesarean section delivery was performed, along with radical hysterectomy.
  • No complications to the neonates or to the mother due to the therapy were observed.
  • Exclusion of nodal metastasis may improve oncologic outcomes, and neoadjuvant chemotherapy should be administered when indicated.
  • [MeSH-major] Adenocarcinoma / surgery. Lymph Node Excision. Pregnancy Complications, Neoplastic / surgery. Pregnancy, Multiple. Uterine Cervical Neoplasms / surgery
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Chemotherapy, Adjuvant. Cisplatin / therapeutic use. Female. Humans. Hysterectomy. Laparoscopy. Neoplasm Staging. Pelvis / pathology. Pelvis / surgery. Pregnancy. Treatment Outcome. Twins


9. Lu KH, Burke TW: Early cervical cancer. Curr Treat Options Oncol; 2000 Jun;1(2):147-55
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early cervical cancer.
  • Early cervical cancer includes a broad range of disease, from clinically undetectable microinvasive cancer to large, bulky tumors that replace the entire cervix.
  • Further subgrouping of this category is therefore necessary to define the optimal treatment approach for individual cases.
  • The International Federation of Gynecology and Obstetrics (FIGO) staging system stratifies stage I tumors into two broad categories, stage IA (microinvasive) and stage IB (gross tumor).
  • Management of women with stage IA disease is controversial.
  • Stage IB1 cervical cancer is managed by either radical surgery or radiotherapy with equivalent recurrence and survival rates.
  • In patients with tumors less than 4 cm in diameter, the decision between radical surgery and radiotherapy is guided by patients' overall health and treatment preferences.
  • Radiation therapy is preferred for women who may not tolerate radical surgery.
  • We always prefer primary radiation therapy for patients with tumors larger than 4 cm in diameter.
  • Recent data convincingly demonstrate that the addition of cisplatin-based chemotherapy significantly improves overall survival rates in cervical cancer patients who undergo radiation therapy.
  • [MeSH-major] Uterine Cervical Neoplasms / therapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Clinical Trials as Topic. Combined Modality Therapy. Female. Humans. Hysterectomy. Immunotherapy, Active. Neoplasm Staging. Prognosis. Radiotherapy

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 1993 Nov;51(2):193-6 [8276293.001]
  • [Cites] Cancer. 1991 Feb 15;67(4):1037-45 [1991252.001]
  • [Cites] Obstet Gynecol. 1986 Sep;68(3):353-6 [3737057.001]
  • [Cites] Cancer. 1999 Dec 1;86(11):2273-9 [10590368.001]
  • [Cites] Gynecol Oncol. 1989 Jun;33(3):265-72 [2722048.001]
  • [Cites] Gynecol Oncol. 1989 Dec;35(3):314-20 [2599466.001]
  • [Cites] N Engl J Med. 1999 Apr 15;340(15):1154-61 [10202166.001]
  • [Cites] N Engl J Med. 1999 Apr 15;340(15):1137-43 [10202164.001]
  • [Cites] Am J Obstet Gynecol. 1998 Dec;179(6 Pt 1):1491-6 [9855586.001]
  • [Cites] Am J Obstet Gynecol. 1985 Sep 15;153(2):164-72 [4037011.001]
  • (PMID = 12057052.001).
  • [ISSN] 1527-2729
  • [Journal-full-title] Current treatment options in oncology
  • [ISO-abbreviation] Curr Treat Options Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 10
  •  go-up   go-down


10. Lee JM, Lee KB, Nam JH, Ryu SY, Bae DS, Park JT, Kim SC, Cha SD, Kim KR, Song SY, Kang SB: Prognostic factors in FIGO stage IB-IIA small cell neuroendocrine carcinoma of the uterine cervix treated surgically: results of a multi-center retrospective Korean study. Ann Oncol; 2008 Feb;19(2):321-6
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors in FIGO stage IB-IIA small cell neuroendocrine carcinoma of the uterine cervix treated surgically: results of a multi-center retrospective Korean study.
  • BACKGROUND: To determine the clinical and pathologic prognostic factors in surgically treated patients with International Federation of Gynecology and Obstetrics (FIGO) stage IB-IIA small cell neuroendocrine carcinoma of the uterine cervix (SCNEC).
  • PATIENTS AND METHODS: We retrospectively reviewed a total of 68 patients with FIGO stage IB-IIA SCNEC surgically treated from January 1997 to December 2003 in Korea.
  • RESULTS: Of the 68 patients, 43 had FIGO stage IB1 SCNEC, 15 had stage IB2, and 10 had stage IIA.
  • Seven were treated with radical surgery alone; 11 with neoadjuvant chemotherapy (NACT) followed by radical surgery; 24 with radical surgery followed by adjuvant chemotherapy; and 26 with radical surgery followed by adjuvant radiation or chemoradiation.
  • Univariate and multivariate analysis showed that FIGO stage was predictive of poor prognosis.
  • Adjuvant chemoradiation did not improve survival compared with adjuvant chemotherapy alone.
  • CONCLUSIONS: FIGO stage may act as a surrogate for factors prognostic of survival.
  • Primary radical surgery followed by adjuvant chemotherapy is the preferred treatment modality for patients with early stage SCNEC.

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17962205.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


11. Landoni F, Parma G, Peiretti M, Zanagnolo V, Sideri M, Colombo N, Maggioni A: Chemo-conization in early cervical cancer. Gynecol Oncol; 2007 Oct;107(1 Suppl 1):S125-6
Hazardous Substances Data Bank. EPIRUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemo-conization in early cervical cancer.
  • OBJECTIVES: The aim of the present study is to support the safety and feasibility of chemo-conization for early-stage cervical tumor in young patients wishing to preserve their fertility.
  • METHODS: Between October 2004 and November 2006, eleven patients were scheduled for conservative treatment.
  • Subjects were selected for this treatment on the basis of favorable cervical tumors (<3 cm) and a desire to maintain fertility.
  • All patients underwent neoadjuvant chemotherapy followed by conization or conization alone with pelvic lymphadenectomy.
  • RESULTS AND CONCLUSIONS: The mean age of the eleven patients was 32 (range: 24-41), Figo Stage was IB1 in 8 cases and 3 cases were Stage IA2.
  • Histological findings were squamous cell carcinoma in 5 patients and adenocarcinoma in 6 patients.
  • Two patients were treated with TEP regimen every 3 weeks for three courses, while one patient had adjuvant chemotherapy with TEP.
  • Although the number is small, in selected patients this conservative approach seems to be feasible to cure early-stage cervical cancer therefore maintaining fertility.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / surgery
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant. Conization / methods. Epirubicin / administration & dosage. Female. Fertility. Humans. Ifosfamide / administration & dosage. Paclitaxel / administration & dosage

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17727935.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 3Z8479ZZ5X / Epirubicin; P88XT4IS4D / Paclitaxel; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


12. Suprasert P, Srisomboon J, Charoenkwan K, Siriaree S, Cheewakriangkrai C, Kietpeerakool C, Phongnarisorn C, Sae-Teng J: Twelve years experience with radical hysterectomy and pelvic lymphadenectomy in early stage cervical cancer. J Obstet Gynaecol; 2010 Apr;30(3):294-8
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Twelve years experience with radical hysterectomy and pelvic lymphadenectomy in early stage cervical cancer.
  • The objective of this study was to evaluate the outcome, prognostic factors and complications of early stage cervical cancer patients treated with radical hysterectomy and pelvic lymphadenectomy (RHPL).
  • The medical records of cervical cancer patients undergoing RHPL at Chiang Mai University Hospital over 12 years, between January 1995 and December 2006 were reviewed.
  • The most common histology was squamous cell carcinoma (67%) followed by adenocarcinoma (23%).
  • The distribution of FIGO staging was: stage IA 8.7%; stage IB 15.8%; stage IB1 61%; stage IB2 6.2%; and stage IIA 8.5%.
  • A total of 66.5% of patients underwent RHPL without adjuvant treatment; 12.1% received neoadjuvant chemotherapy.
  • Stage IB2/IIA, non-squamous cell carcinoma, nodal involvement and positive vaginal margins were independent, significant, poor prognostic factors.
  • It was concluded that early stage cervical cancer patients treated with RHPL have long-term favourable outcome with minimal morbidity.
  • Stage IB2 and IIA, non-squamous cell carcinoma, nodal and vaginal involvement were independent adverse prognostic factors.
  • [MeSH-major] Adenocarcinoma / surgery. Carcinoma, Squamous Cell / surgery. Hysterectomy. Lymph Node Excision. Uterine Cervical Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Chemotherapy, Adjuvant. Connective Tissue / pathology. Disease-Free Survival. Female. Humans. Lymphatic Metastasis. Middle Aged. Neoplasm Invasiveness. Neoplasm Recurrence, Local / epidemiology. Neoplasm Staging. Prognosis. Proportional Hazards Models. Young Adult

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Hysterectomy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20373935.001).
  • [ISSN] 1364-6893
  • [Journal-full-title] Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology
  • [ISO-abbreviation] J Obstet Gynaecol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


13. Huang CY, Chen YL, Chu TC, Cheng WF, Hsieh CY, Lin MC: Prognostic factors in women with early stage small cell carcinoma of the uterine cervix. Oncol Res; 2009;18(5-6):279-86
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors in women with early stage small cell carcinoma of the uterine cervix.
  • Small cell carcinoma of the uterine cervix (SCCUC) is an uncommon, aggressive disease accounting for less than 5% of all cervical cancers.
  • Due to its rarity, definitive treatment strategies have not been developed.
  • Our aim was to analyze the clinical factors, treatment modalities, sites of relapse, and overall survival of women with early stage SCCUC and thus determine prognostic factors.
  • The clinical records of 18 women diagnosed with stage IB1 to IIA SCCUC were reviewed, and patient characteristics and treatment modalities were analyzed to determine the prognostic factors for disease-free survival (DFS) and overall survival (OS).
  • International Federation of Gynecology and Obstetrics (FIGO) stage and lymph node metastasis were significant prognostic factors of OS as determined by multivariate analysis (p < 0.05).
  • Radical hysterectomy followed by adjuvant chemotherapy resulted in higher 2-year survival rates compared to radical hysterectomy followed by adjuvant radiotherapy (62.5% vs. 16.7%); however, the difference was not statistically significant due to the small sample size.
  • FIGO stage and lymph node metastasis are significant indicators of OS in patients with early stage SCCUC.
  • Further larger scale analysis is warranted to determine whether adjuvant chemotherapy may facilitate a better prognosis than adjuvant radiotherapy.
  • [MeSH-major] Carcinoma, Small Cell / pathology. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Humans. Lymphatic Metastasis. Middle Aged. Prognosis. Radiotherapy, Adjuvant. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20225765.001).
  • [ISSN] 0965-0407
  • [Journal-full-title] Oncology research
  • [ISO-abbreviation] Oncol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Marnitz S, Köhler C, Roth C, Füller J, Bischoff A, Wendt T, Schneider A, Budach V: Stage-adjusted chemoradiation in cervical cancer after transperitoneal laparoscopic staging. Strahlenther Onkol; 2007 Sep;183(9):473-8
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stage-adjusted chemoradiation in cervical cancer after transperitoneal laparoscopic staging.
  • PURPOSE: To evaluate the impact of transperitoneal laparoscopic staging on choice of subsequent therapy including oncologic outcome and toxicity of chemoradiation after surgical staging.
  • PATIENTS AND METHODS: 101 patients with cervical cancer FIGO IB1-IVB underwent chemoradiation after transperitoneal laparoscopic staging.
  • RESULTS: 101 women (FIGO IB1-IVB) were laparoscopically staged.
  • Only 17/101 patients (17%) retained their original FIGO stage after laparoscopy.
  • CONCLUSION: In patients with cervical cancer, laparoscopic staging led to an upstaging of 83% of cases with significant impact on therapeutic strategies.
  • Pretherapeutic laparoscopic staging should be the basis of the primary chemoradiation in patients with cervical cancer.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brachytherapy. Carcinoma, Adenosquamous / radiotherapy. Carcinoma, Squamous Cell / radiotherapy. Laparoscopy. Lymphatic Metastasis / radiotherapy. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / radiotherapy
  • [MeSH-minor] Carboplatin / administration & dosage. Cisplatin / administration & dosage. Combined Modality Therapy. Drug Administration Schedule. Female. Fluorouracil / administration & dosage. Follow-Up Studies. Humans. Lymph Node Excision. Neoplasm Invasiveness. Neoplasm Staging. Radiotherapy Dosage. Rectum / pathology. Survival Rate. Urinary Bladder / pathology


15. Abali H, Eren OO, Erman M, Uner AH, Kose F, Guler N: Coincidental detection of T-cell rich B cell lymphoma in the para-aortic lymph nodes of a woman undergoing lymph node dissection for cervical cancer: a case report. Int J Gynecol Cancer; 2003 Sep-Oct;13(5):687-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Coincidental detection of T-cell rich B cell lymphoma in the para-aortic lymph nodes of a woman undergoing lymph node dissection for cervical cancer: a case report.
  • The diagnosis of cervical squamous cell carcinoma with concurrent T-cell rich B cell lymphoma in dissected lymph nodes has not been reported to our knowledge.
  • In our case, the biopsy of an exophytic lesion at the uterine cervix showed squamous cell carcinoma in a 50-year-old woman presenting with postcoital bleeding.
  • Type III hysterectomy, bilateral salpingo-oophorectemy, bilateral pelvic, para-aortic lymph node dissections were performed.
  • Pathologic examination revealed a T-cell rich B cell lymphoma in some lymph nodes beside squamous cell carcinoma in several of others.
  • The cervical carcinoma was staged as FIGO clinical stage IB1 and the lymphoma as Ann Arbor IIA.
  • Six cycles of CHOP (cyclophosphamide, adriamycin, vincristine, and prednisolon) chemotherapy for the lymphoma and concomitant pelvic chemoradiotherapy with cisplatin for cervical cancer were given.
  • In this rare coincidence, the best available therapy for each of the diseases should be considered individually.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / secondary. Lymph Nodes / pathology. Lymphoma, B-Cell / pathology. Neoplasms, Multiple Primary / pathology. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy, Needle. Combined Modality Therapy. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Female. Humans. Immunohistochemistry. Lymph Node Excision / methods. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Prednisone / therapeutic use. Prognosis. Radiotherapy, Adjuvant. Risk Assessment. T-Lymphocytes / pathology. Treatment Outcome. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [RetractionIn] Int J Gynecol Cancer. 2015 Jul;25(6):1142 [26098094.001]
  • (PMID = 14675356.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Duplicate Publication; Journal Article; Retracted Publication
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


16. Chung JJ, Namiki T, Johnson DW: Cervical cancer metastasis to the scalp presenting as alopecia neoplastica. Int J Dermatol; 2007 Feb;46(2):188-9
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cervical cancer metastasis to the scalp presenting as alopecia neoplastica.
  • A 45-year-old Japanese woman was diagnosed in 1996 with squamous cell cancer of the cervix following an abnormal Papanicolaou smear and subsequent diagnostic conization.
  • She underwent total abdominal hysterectomy with pelvic lymphadenectomy and was found to have poorly differentiated squamous cell carcinoma, International Federation of Gynecology and Obstetrics (FIGO) stage IB1.
  • She remained asymptomatic until 2003 when she presented with obstructive uropathy with acute renal failure and hydronephrosis, suspected to be from the recurrence of cervical cancer.
  • This was confirmed when computerized tomography (CT)-guided lymph node biopsy showed squamous cell carcinoma of the para-aortic lymph nodes histologically consistent with the cervical primary.
  • In addition, there was evidence of lumbar spine metastasis by positron emission tomography (PET) and bone scans.
  • She received several courses of chemotherapy with cisplatin and 5-fluorouracil (5FU), as well as radiation therapy.
  • The scalp specimen was histologically identical with biopsy specimens of the cervical primary (Fig. 2b).
  • The patient decided against further treatment for her advanced cervical cancer but did accept hydromorphone for pain.
  • [MeSH-major] Alopecia / etiology. Head and Neck Neoplasms / secondary. Neoplasms, Squamous Cell / secondary. Scalp. Skin Neoplasms / secondary. Uterine Cervical Neoplasms / pathology


17. Lee KB, Lee JM, Park CY, Lee KB, Cho HY, Ha SY: What is the difference between squamous cell carcinoma and adenocarcinoma of the cervix? A matched case-control study. Int J Gynecol Cancer; 2006 Jul-Aug;16(4):1569-73
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] What is the difference between squamous cell carcinoma and adenocarcinoma of the cervix? A matched case-control study.
  • The objective of this study was to investigate the efficacy of treatment strategies in patients with adenocarcinoma (AC) of the cervix and compare it with those with squamous cell carcinoma (SCC) of the cervix.
  • Women with FIGO (1994) stage IB1 AC, especially pathologic tumor size of 2-4 cm, treated with class III hysterectomy, were compared with those with SCC treated with comparable strategy in a case-controlled study.
  • Primary radical surgery followed by adjuvant therapy, same as for SCC, would be acceptable for AC with pathologic tumor size of 2-4 cm.
  • Although it was difficult to determine whether AC recurred more systemically, more effective treatment strategies than those currently available for AC should be considered to reduce the systemic recurrence.
  • [MeSH-major] Adenocarcinoma / therapy. Carcinoma, Squamous Cell / therapy. Uterine Cervical Neoplasms / therapy
  • [MeSH-minor] Adenocarcinoma, Mucinous / drug therapy. Adenocarcinoma, Mucinous / surgery. Adenocarcinoma, Mucinous / therapy. Adult. Aged. Antineoplastic Agents / therapeutic use. Case-Control Studies. Chemotherapy, Adjuvant. Combined Modality Therapy. Disease-Free Survival. Endometrial Neoplasms / drug therapy. Endometrial Neoplasms / surgery. Endometrial Neoplasms / therapy. Female. Humans. Hysterectomy. Lymphatic Metastasis. Middle Aged. Neoplasm Invasiveness / pathology. Neoplasm Recurrence, Local / diagnosis. Neoplasm Staging. Retrospective Studies. Stromal Cells / pathology. Survival Rate


18. Nijhuis ER, van der Zee AG, in 't Hout BA, Boomgaard JJ, de Hullu JA, Pras E, Hollema H, Aalders JG, Nijman HW, Willemse PH, Mourits MJ: Gynecologic examination and cervical biopsies after (chemo) radiation for cervical cancer to identify patients eligible for salvage surgery. Int J Radiat Oncol Biol Phys; 2006 Nov 1;66(3):699-705
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gynecologic examination and cervical biopsies after (chemo) radiation for cervical cancer to identify patients eligible for salvage surgery.
  • PURPOSE: The aim of this study was to evaluate efficacy of gynecologic examination under general anesthesia with cervical biopsies after (chemo) radiation for cervical cancer to identify patients with residual disease who may benefit from salvage surgery.
  • METHODS AND MATERIALS: In a retrospective cohort study data of all cervical cancer patients with the International Federation of Gynecology and Obstetrics (FIGO) Stage IB1 to IVA treated with (chemo) radiation between 1994 and 2001 were analyzed.
  • Patients underwent gynecologic examination under anesthesia 8 to 10 weeks after completion of treatment.
  • Cervical biopsy samples were taken from patients judged to be operable.
  • In case of residual cancer, salvage surgery was performed.
  • RESULTS: Between 1994 and 2001, 169 consecutive cervical cancer patients received primary (chemo) radiation, of whom 4 were lost to follow-up.
  • CONCLUSIONS: Gynecologic examination under anesthesia 8 to 10 weeks after (chemo) radiation with cervical biopsies allows identification of those cervical cancer patients who have residual local disease, of whom a small but significant proportion may be salvaged by surgery.
  • [MeSH-major] Cervix Uteri / pathology. Salvage Therapy. Uterine Cervical Neoplasms
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Adenocarcinoma / radiotherapy. Adenocarcinoma / surgery. Adult. Aged. Anesthesia, General. Biopsy. Carcinoma, Adenosquamous / drug therapy. Carcinoma, Adenosquamous / pathology. Carcinoma, Adenosquamous / radiotherapy. Carcinoma, Adenosquamous / surgery. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / radiotherapy. Carcinoma, Squamous Cell / surgery. Combined Modality Therapy / methods. Female. Follow-Up Studies. Humans. Middle Aged. Neoplasm, Residual. Retrospective Studies. Survival Analysis

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16904839.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Deng GH, Zhang X, Wu LY: [Clinicopathological analysis of nine cases of small cell carcinoma of the uterine cervix]. Zhonghua Zhong Liu Za Zhi; 2010 Mar;32(3):199-202
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinicopathological analysis of nine cases of small cell carcinoma of the uterine cervix].
  • OBJECTIVE: To investigate the clinicopathologic characteristics, therapy and prognostic factors of small cell carcinoma of the uterine cervix (SCCC).
  • METHODS: Nine patients with SCCC underwent radical hysterectomy at the Cancer Hospital of CAMS between 2000 to 2009.
  • According to FIGO staging criteria, six patients were stage Ib1 disease, 2 stage Ib2 and 1 stage IVb.
  • All patients received postoperative chemotherapy, with or without radiotherapy.
  • It is necessary to use multimodality treatment for SCCC, especially the chemotherapy.
  • [MeSH-major] Carcinoma, Small Cell / pathology. Hysterectomy. Nuclear Proteins / metabolism. Transcription Factors / metabolism. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adult. Antigens, CD56 / metabolism. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chromogranin A / metabolism. Cisplatin / therapeutic use. Combined Modality Therapy. Cyclin-Dependent Kinase Inhibitor p16 / metabolism. Female. Follow-Up Studies. Humans. Lymph Node Excision. Middle Aged. Neoplasm Staging. Phosphopyruvate Hydratase / metabolism. Radiotherapy, High-Energy. Survival Rate. Synaptophysin / metabolism. Taxoids / therapeutic use

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Hysterectomy.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20450588.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD56; 0 / Chromogranin A; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Nuclear Proteins; 0 / Synaptophysin; 0 / Taxoids; 0 / Transcription Factors; 0 / thyroid nuclear factor 1; EC 4.2.1.11 / Phosphopyruvate Hydratase; Q20Q21Q62J / Cisplatin; TP protocol
  •  go-up   go-down


20. Abali H, Eren OO, Erman M, Uner AH, Kose F, Guler N: Coincidental detection of T-cell rich B-cell lymphoma in the paraaortic lymph nodes of a woman undergoing lymph node dissection for cervical cancer. Int J Gynecol Cancer; 2003 Jul-Aug;13(4):548-50
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Coincidental detection of T-cell rich B-cell lymphoma in the paraaortic lymph nodes of a woman undergoing lymph node dissection for cervical cancer.
  • The diagnosis of cervical squamous cell carcinoma with concurrent T-cell rich B-cell lymphoma in dissected lymph nodes has not been reported to our knowledge.
  • The biopsy of an exophytic lesion at the uterine cervix showed squamous cell carcinoma in a 50-year-old woman presenting with postcoital bleeding.
  • Type III hysterectomy, bilateral salpingo-oophorectemy, bilateral pelvic, paraaortic lymph node dissections were performed.
  • Pathologic examination revealed a T-cell rich B-cell lymphoma in some lymph nodes beside squamous cell carcinoma in several of others.
  • The cervical carcinoma was staged as FIGO clinical stage IB1 and the lymphoma as Ann Arbor IIA.
  • Six cycles of CHOP (cyclophosphamide, adriamycin, vincristine, and prednisone) chemotherapy for the lymphoma and concomitant pelvic chemo-radiotherapy with cisplatin for cervical cancer were given.
  • In this rare coincidence; the best available therapy for each of the diseases should be considered individually.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / secondary. Lymph Nodes / pathology. Lymphoma, B-Cell / pathology. Neoplasms, Multiple Primary / pathology. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy, Needle. Combined Modality Therapy. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Female. Humans. Immunohistochemistry. Lymph Node Excision / methods. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Prednisone / therapeutic use. Prognosis. Radiotherapy, Adjuvant. Risk Assessment. T-Lymphocytes / pathology. Treatment Outcome. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12911737.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Duplicate Publication; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


21. Xiao Y, Li JD, Shi HL, Liu JH, Feng YL, Li MD: [Predictive value of in vitro MTT assay chemosensitivity test of cytotoxic drug activity in cervical cancer]. Ai Zheng; 2007 Apr;26(4):386-9
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Predictive value of in vitro MTT assay chemosensitivity test of cytotoxic drug activity in cervical cancer].
  • BACKGROUND & OBJECTIVE: In recent years, the neoadjuvant chemotherapy for cervical cancer has evoked more and more attention and has been used widely.
  • But the chemosensitivity of individuals to various antitumor drugs is different.
  • This study was to investigate the chemosensitivity of cervical cancer cells to antitumor drugs using in vitro MTT assay chemosensitivity test.
  • METHODS: The sensitivity of fresh human cervical cancer cells from 32 patients to 9 cytotoxic drugs was tested using in vitro MTT assay.
  • RESULTS: The cytotoxic activities of the 9 drugs for cervical cancer were in sequence from high to low as follows: liposomal paclitaxel, taxol, carboplatin (CBP), ifosfamide (IFO), etoposide (VP-16), 5-fluorouracil (5-FU), cisplatin (DDP), bleomycin (BLM), and cyclophosphamide (CTX).
  • Generally, cervical cancer cells were more sensitive to paclitaxel, taxol, and CBP than to other drugs (P<0.05) with inhibition rates of 56.56%, 55.66%, and 46.81%, respectively.
  • Stage Ib1 cervical cancer cells were more sensitive to taxol, paclitaxel, and CBP than to other drugs with inhibition rates of 58.71%, 53.00%, and 49.25%, respectively; stage Ib2 cervical cancer cells were more sensitive to paclitaxel and taxol than to other drugs with inhibition rates of 65.26% and 50.06%.
  • Both moderately and poorly differentiated squamous cell cancer cells were more sensitive to taxol, paclitaxel, and CBP than to other drugs with inhibition rates of 52.01%, 49.21%, and 40.02% for the former, and 60.02%, 61.16%, and 48.75% for the latter.
  • CONCLUSIONS: MTT assay, a sensitive and widely used chemosensitivity testing method, is helpful in sensitive drug screening and neoadjuvant chemotherapy regimen selection for cervical cancer.
  • Cervical cancer cells are more sensitive to paclitaxel, taxol, and CBP than to other tested drugs in this study.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Carcinoma, Squamous Cell / pathology. Cell Survival / drug effects. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adult. Bleomycin / pharmacology. Carboplatin / pharmacology. Cells, Cultured. Cisplatin / pharmacology. Cyclophosphamide / pharmacology. Drug Screening Assays, Antitumor / methods. Etoposide / pharmacology. Female. Fluorouracil / pharmacology. Humans. Middle Aged. Neoplasm Staging. Paclitaxel / pharmacology


22. Liu H, Peng ZL, Lou JY, Ping W: Pregnancy after neoadjuvant chemotherapy followed by pelvic lymphadenectomy and radical trachelectomy in bulky stage IB1 cervical cancer: a case report. Aust N Z J Obstet Gynaecol; 2008 Oct;48(5):517-8
MedlinePlus Health Information. consumer health - Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pregnancy after neoadjuvant chemotherapy followed by pelvic lymphadenectomy and radical trachelectomy in bulky stage IB1 cervical cancer: a case report.
  • [MeSH-major] Hysterectomy / adverse effects. Pregnancy / physiology. Pregnancy Outcome. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / surgery
  • [MeSH-minor] Female. Gynecologic Surgical Procedures. Humans. Lymph Node Excision. Neoadjuvant Therapy. Neoplasm Staging. Young Adult


23. Bader AA, Winter R, Tamussino KF: Re: Plante M., Lau S., Brydon L., Swenerton K., Leblanc R., Roy M. Neoadjuvant chemotherapy followed by vaginal radical trachelectomy in bulky stage IB1 cervical cancer: case report. Gynecol Oncol 2006;101:367-70. Gynecol Oncol; 2006 Oct;103(1):374; author reply 374-5
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Re: Plante M., Lau S., Brydon L., Swenerton K., Leblanc R., Roy M. Neoadjuvant chemotherapy followed by vaginal radical trachelectomy in bulky stage IB1 cervical cancer: case report. Gynecol Oncol 2006;101:367-70.
  • [MeSH-major] Sentinel Lymph Node Biopsy. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / surgery
  • [MeSH-minor] Female. Gynecologic Surgical Procedures. Humans. Lymphatic Metastasis. Neoadjuvant Therapy


24. Maneo A, Mangioni C: Re: neoadjuvant chemotheraphy followed by vaginal radical trachelectomy in bulky stage IB1 cervical cancer. Gynecol Oncol; 2006 Nov;103(2):763-4; author reply 764-5
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Re: neoadjuvant chemotheraphy followed by vaginal radical trachelectomy in bulky stage IB1 cervical cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Uterine Cervical Neoplasms / drug therapy
  • [MeSH-minor] Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Female. Gynecologic Surgical Procedures. Humans. Ifosfamide / administration & dosage. Infusions, Parenteral. Neoadjuvant Therapy. Paclitaxel / administration & dosage. Randomized Controlled Trials as Topic

  • Genetic Alliance. consumer health - Vaginal cancer.
  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Gynecol Oncol. 2006 May;101(2):367-70 [16542714.001]
  • (PMID = 16952390.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down






Advertisement